Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Novo Nordisk, maintaining a price target of $160.
September 09, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Novo Nordisk, maintaining a price target of $160, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and maintenance of a $160 price target by Cantor Fitzgerald suggests a positive outlook for Novo Nordisk's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100